Related Experiment Videos
Oral tolerance and inflammatory bowel disease
1Evanston Northwestern Healthcare Research Institute and Department of Biology, Molecular Biology and Cell Biology, Northwestern University, Illinois, USA.
Current Opinion in Gastroenterology
|October 13, 2005
Summary
Oral tolerance therapy shows promise for Crohn's disease, but human immune responses differ from mice. Further research into the human mucosal immune system is crucial for successful autoimmune disease treatment.
Area of Science:
- Immunology
- Gastroenterology
Background:
- Oral tolerance is the mucosal immune system's active inhibition of systemic responses to ingested antigens.
- Breakdown of oral tolerance is implicated in inflammatory bowel disease (IBD) pathogenesis.
- Despite this, oral tolerance therapy is being explored for IBD, including Crohn's disease.
Purpose of the Study:
- To review advances in understanding oral tolerance.
- To explore the relationship between oral tolerance and IBD.
- To assess the potential of oral tolerance therapy for IBD.
Main Methods:
- Review of recent scientific literature on oral tolerance.
- Analysis of clinical trial data for oral tolerance therapy in Crohn's disease.
- Examination of experimental studies on oral tolerance induction in IBD models.
Main Results:
- A trial in Israeli Crohn's disease patients yielded promising results.
- Experimental induction of oral tolerance using a neoantigen was unsuccessful in IBD patients.
- Significant differences exist between oral tolerance mechanisms in mice and humans.
Conclusions:
- Understanding human mucosal immunity is key to advancing oral tolerance therapies.
- Current approaches may not fully translate from animal models to human IBD treatment.
- Further research is needed to optimize oral tolerance therapy for autoimmune and chronic inflammatory disorders.